Login / Signup

Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.

Myungsun ShimWoo Jin BangCheol Young OhYong Seong LeeJin Seon Cho
Published in: Investigative and clinical urology (2019)
Three LHRH agonists showed comparable efficacy for achieving castration when the castration threshold was 50 or 20 ng/dL. However, triptorelin was the most potent LHRH agonist, achieving the lowest mean testosterone levels and the highest rate of chemical castration at <10 ng/dL testosterone.
Keyphrases
  • prostate cancer
  • randomized controlled trial
  • replacement therapy
  • systematic review
  • anti inflammatory